Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
| Autor: | Roger Jungedal, Elin Engdahl, Jan Hillert, Ryan Ramanujam, Anna Fogdell-Hahn, Ajith Sominanda, Malin Lundkvist, Helga Westerlind |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug
Multiple Sclerosis biology Interferon beta business.industry media_common.quotation_subject Immunogenicity Multiple sclerosis Interferon-beta medicine.disease Antibodies Neutralizing Clinical Practice Neurology Seroepidemiologic Studies Immunology biology.protein Humans Immunologic Factors Seroprevalence Medicine Neurology (clinical) Antibody Protein A business media_common |
| Zdroj: | Multiple Sclerosis Journal. 18:1775-1781 |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/1352458512446036 |
| Popis: | Background: Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003–2004 was 32% in a cross-sectional analysis of routine data. Objectives: The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNβ preparations used for treatment of multiple sclerosis patients had changed in 2009–2010. Methods: This study included 1296 patients, analysed for NAbs with the myxovirus resistance protein A gene expression assay in 2009–2010. Results: The seroprevalence of NAbs had decreased to 19% in 2009–2010, which is significantly lower compared with the previous study in 2003–2004 ( pConclusions: NAb seroprevalence has decreased since NAb monitoring became clinical practice in 2003, especially for patients with high NAb titres. This might be due to the stricter monitoring of NAb titres that prompt NAb positive patients to stop treatment, to preferential use of less immunogenic drugs and to alteration of drug formulations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|